{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:38:28Z","timestamp":1782185908101,"version":"3.54.5"},"reference-count":101,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.numecd.2025.104033","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T12:09:26Z","timestamp":1743682166000},"page":"104033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view"],"prefix":"10.1016","volume":"35","author":[{"given":"Ermanno","family":"Nardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prastaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-1680","authenticated-orcid":false,"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fontanarosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Perrone","family":"Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.numecd.2025.104033_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11892-019-1239-x","article-title":"Diabetes and cardiovascular disease: an update","volume":"19","author":"Almourani","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"10.1016\/j.numecd.2025.104033_bib3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","article-title":"Diabetes mellitus and cardiovascular disease","volume":"39","author":"Schmidt","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.numecd.2025.104033_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.numecd.2025.104033_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11892-019-1244-0","article-title":"Personalized management of type 2 diabetes","volume":"19","author":"Peter","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.numecd.2025.104033_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.diabres.2019.04.004","article-title":"The role of education in type 2 diabetes treatment","volume":"151","author":"\u015awi\u0105toniowska","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.numecd.2025.104033_bib10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/medicina58101475","article-title":"An update on the current and emerging use of thiazolidinediones for type 2 diabetes","volume":"58","author":"Giglio","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1568026620666191224141617","article-title":"Mechanisms and characteristics of sulfonylureas and glinides","volume":"20","author":"Lv","year":"2020","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00003495-198835030-00003","article-title":"Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential","volume":"35","author":"Clissold","year":"1988","journal-title":"Drugs"},{"issue":"9548","key":"10.1016\/j.numecd.2025.104033_bib13","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.numecd.2025.104033_bib15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"13","key":"10.1016\/j.numecd.2025.104033_bib16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2165\/00003495-200767130-00002","article-title":"Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?","volume":"67","author":"Bell","year":"2007","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.therap.2021.10.002","article-title":"Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials","volume":"77","author":"Sun","year":"2022","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00125-017-4473-2","article-title":"Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)","volume":"61","author":"Agrawal","year":"2018","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2025.104033_bib19","first-page":"S83","article-title":"6. Glycemic targets: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.numecd.2025.104033_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2337\/dci18-0018","article-title":"WT. A1C targets should Be personalized to maximize benefits while limiting risks","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.numecd.2025.104033_bib21","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2337\/dc20-2439","article-title":"Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88","volume":"44","author":"Lind","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.numecd.2025.104033_bib22","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Control","year":"2009","journal-title":"Diabetologia"},{"issue":"9131","key":"10.1016\/j.numecd.2025.104033_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"10.1016\/j.numecd.2025.104033_bib24","first-page":"854","article-title":"UK prospective diabetes study (UKPDS) group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.numecd.2025.104033_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.numecd.2025.104033_bib27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.numecd.2025.104033_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00125-021-05567-4","article-title":"Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial","volume":"65","author":"Pigeyre","year":"2022","journal-title":"Diabetologia"},{"issue":"39","key":"10.1016\/j.numecd.2025.104033_bib30","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2025.104033_bib31","first-page":"S8","article-title":"1. Improving care and promoting health in populations: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.2012.638283","article-title":"Metformin and heart failure: never say never again","volume":"13","author":"Papanas","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2025.104033_bib34","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"On behalf of the American diabetes association. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.numecd.2025.104033_bib35","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.2337\/dcS15-3007","article-title":"Clinical considerations for use of initial combination therapy in type 2 diabetes","volume":"39","author":"Cahn","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.numecd.2025.104033_bib37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/dom.12233","article-title":"Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis","volume":"16","author":"Phung","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"10208","key":"10.1016\/j.numecd.2025.104033_bib38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014908","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"10.1016\/j.numecd.2025.104033_bib40","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.numecd.2025.104033_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001225","article-title":"Impact and efficacy of mobile health intervention in the management of diabetes and hypertension: a systematic review and meta-analysis","volume":"8","author":"Mao","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"10.1016\/j.numecd.2025.104033_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dme.14058","article-title":"Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK","volume":"36","author":"Bain","year":"2019","journal-title":"Diabet Med"},{"issue":"8","key":"10.1016\/j.numecd.2025.104033_bib44","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jamainternmed.2014.2894","article-title":"Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus","volume":"174","author":"Vijan","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.numecd.2025.104033_bib45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.numecd.2025.104033_bib46","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cpt.1307","article-title":"A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses","volume":"105","author":"Maloney","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1503\/cmaj.081041","article-title":"Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis","volume":"180","author":"Singh","year":"2009","journal-title":"CMAJ (Can Med Assoc J)"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib48","article-title":"Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus","author":"Horvath","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib49","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2025.104033_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diabres.2016.10.022","article-title":"Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U\/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy","volume":"124","author":"Owens","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.numecd.2025.104033_bib51","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.numecd.2025.104033_bib52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.12618","article-title":"New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)","volume":"18","author":"Terauchi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.numecd.2025.104033_bib56","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"Yki-J\u00e4rvinen","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.numecd.2025.104033_bib57","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.numecd.2025.104033_bib58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/dme.12303","article-title":"BEGIN once Long trial investigators. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial","volume":"30","author":"Rodbard","year":"2013","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2017.7117","article-title":"Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial","volume":"318","author":"Wysham","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.numecd.2025.104033_bib60","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"NN1250-3579 (BEGIN once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S2213-8587(13)70090-1","article-title":"Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial","volume":"2","author":"Rodbard","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.numecd.2025.104033_bib62","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.numecd.2025.104033_bib63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2025.104033_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","article-title":"The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 trial","volume":"200","author":"Wiviott","year":"2018","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.numecd.2025.104033_bib66","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"VERTIS CV investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib67","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"SCORED investigators. Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.numecd.2025.104033_bib69","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.numecd.2025.104033_bib70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.numecd.2025.104033_bib71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.numecd.2025.104033_bib72","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"ELIXA investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.numecd.2025.104033_bib73","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.numecd.2025.104033_bib74","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2013.02.006","article-title":"Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes","volume":"39","author":"Scheen","year":"2013","journal-title":"Diabetes Metab"},{"issue":"14","key":"10.1016\/j.numecd.2025.104033_bib76","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.numecd.2025.104033_bib77","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib78","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"CARMELINA investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.numecd.2025.104033_bib80","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"CAROLINA investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.numecd.2025.104033_bib81","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/dme.12232","article-title":"Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis","volume":"30","author":"Phung","year":"2013","journal-title":"Diabet Med"},{"issue":"11","key":"10.1016\/j.numecd.2025.104033_bib82","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.numecd.2025.104033_bib83","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"Navigator","year":"2010","journal-title":"N Engl J Med"},{"issue":"9493","key":"10.1016\/j.numecd.2025.104033_bib84","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.numecd.2025.104033_bib85","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2025.104033_bib86","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Origin","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.numecd.2025.104033_bib87","first-page":"1995","article-title":"Safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.numecd.2025.104033_bib88","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.numecd.2025.104033_bib89","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.numecd.2025.104033_bib90","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.numecd.2025.104033_bib91","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib92","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"24","key":"10.1016\/j.numecd.2025.104033_bib93","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"SOLOIST-WHF trial investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.numecd.2025.104033_bib95","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2025.104033_bib96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"VIVIDD trial committees and investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.numecd.2025.104033_bib97","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"15","key":"10.1016\/j.numecd.2025.104033_bib98","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.numecd.2025.104033_bib99","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104033_bib100","series-title":"A research study to See how semaglutide works compared to placebo in people with Type 2 Diabetes and Chronic Kidney Disease (FLOW), In: ClinicalTrials.gov","year":"2019"},{"issue":"3","key":"10.1016\/j.numecd.2025.104033_bib101","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin Treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325001875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325001875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T18:35:42Z","timestamp":1753295742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0939475325001875"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104033","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104033"}}